Fig. 2 | Scientific Reports

Fig. 2

From: Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer

Fig. 2

Kaplan Meier estimates for patients with standard of care (SOC) and metastasis directed radiotherapy (MDRT). (A) Freedom of intensification of systemic therapy according to treatment group, intensification consisting either of Androgen receptor pathway inhibitors (ARPI), depicted in B or cytostatic chemotherapy, depicted in C.

Back to article page